




UNDER THE PATENT COOPERATION TREATY (PCT)

-2- * -C12N7/00

(51) International Patent Classification : C12N 7/01, 15/86, 15/38		A1	(11) International Publication Number: WO 91/02788
		(43) International Publication Date:	7 March 1991 (07.03.91)
(21) International Application Number: PCT/GB90/01276		(74) Agent: CRUIKSHANK & FAIRWEATHER : 19 Royal Exchange Square, Glasgow G1 3AE (GB).	
(22) International Filing Date: 14 August 1990 (14.08.90)			
(30) Priority data: 8918616.7 15 August 1989 (15.08.89) GB		(81) Designated States: AT (European patent), AU , BE (European patent), CA , CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI , FR (European patent), GB (European patent), IT (European patent), JP , LU (European patent), NL (European patent), NO , SE (European patent), US .	
(71) Applicant (for all designated States except US): UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW [GB/GB]; No. 2 The Square, University Avenue, Glasgow G12 8QQ (GB).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): PRESTON, Christopher, Maurice [GB/GB]; MRC Virology Unit, Institute of Virology, Church Street, Glasgow G11 5JR (GB). ACE, Christopher, Ian [GB/US]; Dept. of Biochemistry and Molecular Biology, Harvard University, 7 Divinity Avenue, Cambridge, MA 02138 (US).			

(54) Title: **HERPES SIMPLEX VIRUS TYPE 1 MUTANT**



(57) Abstract

A herpes simplex virus type 1 (HSV-1) mutant capable of establishing latent infection in the absence of *in vivo* viral replication in neuronal cells and of expressing an inserted therapeutic gene, which comprising: (i) a DNA sequence change in the gene coding for Vmw65 protein, such as to substantially remove the transducing properties whilst retaining its structural role and thereby preventing *in vivo* replication, the DNA sequence change being achieved by a transition or transversion alteration of 1 to 72 base pairs, an oligonucleotide insert of 3 to 72 base pairs, or a deletion of 3 to 72 base pairs, at a position between amino acids 289 and 412 of the protein; and (ii) a therapeutic gene inserted into a region of the HSV-1 genome which is non-essential for culture of the virus, and a promoter therefor able to express the therapeutic gene in neuronal cells *in vivo*. The preferred insertion site for the therapeutic gene (e.g. tyrosine hydroxylase gene) is within the thymidine kinase gene of HSV *in* 1814.

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TC	Togo
				US	United States of America

HERPES SIMPLEX VIRUS TYPE 1 MUTANTField of the Invention

The present invention relates to a mutant of herpes simplex virus type 1 (HSV-1) capable of establishing efficient latent infection in the absence of in vivo viral replication in neuronal cells and of expressing an inserted therapeutic gene. It is particularly useful for the therapy of neurological disease due to or associated with genetic deficiency.

- 2 -

Background

A distinguishing feature of herpesvirus infections is the ability to persist in the host for long periods in a nonreplicative or latent state. Herpes simplex virus type 1 (HSV-1) establishes latent infection in human peripheral sensory ganglia, and can reactivate to produce recurrent mucocutaneous lesions in the innervated dermatome (for a review see Baichwal and Sugden, 1988; Hill, 1985; Roizman and Sears, 1987). Operationally, the pathogenesis of herpesvirus infections can be divided into several distinct stages which can be studied individually in experimental animal models: acute viral replication, establishment of latency, maintenance, and reactivation (Hill, 1985; Roizman and Sears, 1987). Following inoculation, HSV-1 replicates at the site of inoculation and is transported to sensory ganglia. Replication at the periphery or in sensory ganglia, measured by viral titers of tissue homogenates, may increase the amount of virus that can establish latent infection. During latent infection, HSV-1 DNA can be detected in infected tissues, but infectious virus can not (Deshmane and Fraser, 1989; Efsthathiou et al., 1986; Fraser et al., 1986; Rock and Fraser, 1983). This latent state is often maintained for the life of the host. A variety of stimuli (such as febrile illness and X-ray irradiation) can interrupt the latent state and cause the reappearance of infectious virus, or reactivation.

Most of the information about acute viral replication and gene expression has been obtained in tissue culture systems. The HSV-1 lytic replication cycle has been described as a coordinated process that involves the temporal regulation of at least three viral gene classes: α , β , γ (for a review see Roizman and Sears, 1987). Five immediate early genes (IE, α) have been identified that are first expressed in infected cells prior to viral protein synthesis. Two of these genes, ICP4 and ICP27, are essential for viral replication in cell culture (Dixon and Schaffer, 1980; Preston, 1979; Sacks et al. 1985). The α genes activate β genes, many of which are enzymes involved in nucleotide metabolism, leading in turn to activation of γ genes, many of which are structural components of the mature virus particle. Following corneal inoculation, a broad spectrum of HSV-1 genes from the α , β , and γ gene classes can be detected by in situ hybridization

and Northern blot analysis during the acute phase of viral replication in mouse trigeminal ganglia (Deatly et al., 1987; Spivack and Fraser, 1988a).

There has been recent progress in characterizing HSV-1 gene expression during latent infection. After the first 5-6 days post infection in mice, HSV-1 gene expression in trigeminal ganglia is limited (Spivack and Fraser, 1988a). This correlates with the decline of infectious virus in trigeminal ganglia (Knotts et al., 1974; Steiner et al., 1989). As early as four days post infection, the HSV-1 latency-associated transcripts (LATs; Spivack and Fraser, 1987; Stevens et al., 1987) begin to accumulate in trigeminal ganglia (Spivack and Fraser, 1988a). The LATs are present predominantly in neuronal cell nuclei (Deatly et al., 1987; 1988; Steiner et al., 1988; Stevens et al., 1987; Stroop et al., 1984), and are not extensively polyadenylated (Spivack and Fraser, 1987). These 2.0, 1.5 and 1.45kb transcripts, are encoded by diploid genes within the repeat regions of the viral genome (Spivack and Fraser, 1987). The detailed structure of these genes and their regulatory elements is still incomplete. The 2.0kb LAT is detectable at low levels in infected tissue culture cells (Spivack and Fraser, 1987), and appears to be regulated differently than any of the previously defined classes of HSV-1 genes (Spivack and Fraser, 1988b).

The function of the LATs has only recently been examined; genetic analysis indicates that the LATs are not required for the establishment of latent infection (Javier et al., 1988; Steiner et al., 1989), but that they might play a role in the reactivation process (Steiner et al., 1989). Although a variant HSV-1 virus which does not express the LATs establishes latent infection in mouse trigeminal ganglia, it reactivates in explanted ganglia much more slowly than wild-type virus (Steiner et al., 1989). During the reactivation process there is a lag period before the synthesis of viral RNA, DNA, or infectious virus can be detected (Spivack and Fraser, 1988a). The levels of the LATs decline about two fold during this period, even when reactivation is blocked by inhibitors (Spivack and Fraser, 1988a). Presently, there is little information about the switch to lytic or latent HSV-1 gene expression during the initial stages of infection, or from latent to lytic transcriptional programs during the reactivation

process. It is likely that both viral and cellular transcription factors are important determinants.

Transcription of the HSV-1 IE genes is not detectable during latency (Deatly et al., 1987; Spivack and Fraser, 1987; Steiner et al., 1988; Stevens et al., 1987). However, in tissue culture, IE gene expression is a prerequisite for viral replication (Dixon and Schaffer, 1980; Preston, 1979; Roizman and Sears, 1987; Sacks et al., 1985). Transcription of the IE genes is transinduced by a virion protein, Vmw65 (trans-inducing factor, or α TIF), that is a component of the HSV-1 virion (Batterson and Roizman, 1983; Campbell et al., 1984; O'Hare and Hayward, 1987; Post et al., 1981; Preston et al., 1984). Vmw65 does not bind directly to HSV-1 DNA, but mediates transinduction by association with cellular proteins to form a complex which interacts with the IE regulatory element TAATGARAT (Gerster and Roeder, 1988; McKnight et al., 1987; O'Hare and Goding, 1988; Preston et al., 1988). Since the expression of IE genes is a critical factor in the outcome of HSV-1 infection in tissue culture cells, the presence or absence of functional Vmw65 might be an important determinant of productive and latent infection *in vivo* (Ace et al., 1989; Roizman and Sears, 1987).

An HSV-1 mutant, in1814 (Ace et al., 1989), which contains a 12bp insertion in the coding region of Vmw65, is unable to transinduce IE gene expression, but the altered Vmw65 is incorporated into mature virions. Replication of in1814 during infection is dependent upon the multiplicity of infection (MOI). The Vmw65 defect is partially overcome by infection at high multiplicities. At high MOI (10^2 - 10^3 particles/cell), the expression of ICP0 and ICP27 is significantly reduced, ICP22 slightly reduced, and ICP4 expression is unaffected (Ace et al., 1989). At lower in1814 MOI (1-10 particles/cell), the expression of HSV-1 thymidine kinase, an indicator β gene is profoundly reduced, suggesting that IE gene expression is insufficient to activate the viral replication cycle (Ace et al., 1989).

Summary of the Invention

The present invention provides a herpes simplex virus type 1 (HSV-1) mutant capable of establishing latent infection in the absence of in vivo viral replication in neuronal cells and of expressing an inserted therapeutic gene, which comprises

(i) a DNA sequence change in the gene coding for Vmw65 protein, such as to substantially remove the transinducing properties whilst retaining its structural role and thereby preventing in vivo replication, the DNA sequence change being achieved by a transition or transversion alteration of 1 to 72 base pairs, an oligonucleotide insert of 3 to 72 base pairs, or a deletion of 3 to 72 base pairs, at a position between amino acids 289 and 412 of the protein; and

(ii) a therapeutic gene inserted into a region of the HSV-1 genome which is non-essential for culture of the virus, and a promoter therefor able to express the therapeutic gene in neuronal cells in vivo

The position and size of the DNA sequence change is important, since it is necessary to substantially remove the transinducing properties of the Vmw65 protein (and thereby prevent in vivo replication of the virus and consequent illness of the patient) whilst at the same time retaining the structural properties of the protein required to successfully assemble the complete virion when the virus is cultured. The mutant virus must be capable

of replication under culture conditions so as to be able to produce sufficient quantities of the mutant virus for use, but at the same time the virus should be incapable of replication in vivo. Removal of the transinducing properties of the Vmw65 protein keeps the virus in its latent stage, and prevents progression to active stages of viral replication and expression in vivo. The mutant virus may advantageously be based on the inl8l4 phenotype.

It has been surprisingly found that the insertion of a oligonucleotide insert of the size and at the position stated above, prevents in-vivo replication but otherwise does not prevent necessary functions of the virus. Thus, it is found that the mutant virus is translocated into target neuronal cells as efficiently as "wild-type" HSV-1, that the virus remains in the cells and is not eliminated, that the expression of latency - associated transcripts (LAT's) is unaffected, and that the ability of the virus to enter and remain in its latent stage is also unaffected. These properties allow the mutant virus to be successfully used as a vector for introducing and maintaining therapeutic genes specifically into neuronal cells without substantial elimination thereof. This provides a route for therapy of neuronal genetic deficiencies.

The therapeutic gene is generally a gene associated with a neurological genetic deficiency disease i.e. it compensates for an inherited or acquired genetic

deficiency. Examples of such therapeutic genes include:

- (a) human, rat or mouse tyrosine hydroxylase genes 1, 2 or 3, which are relevant to the alleviation of symptoms of Parkinson's disease;
- (b) human, rat or mouse nerve growth factor beta subunit, for treatment of Alzheimer's disease and Parkinson's disease;
- (c) human, rat or mouse hypoxanthine - guanine phosphoribosyl transferase gene, for the treatment of Lesch-Nyan disease; and
- (d) human beta-hexosaminidase alpha chain gene, for the treatment of Tay-Sachs and Sandhoff's diseases.
- (e) human immunodeficiency virus (HIV) nef gene, for the control of neurological symptoms in HIV-positive individuals

In particular, the in-situ expression of tyrosine hydroxylase by the present HSV-1 mutant may help alleviate the symptoms of Parkinson's disease. Tyrosine hydroxylase is a crucial enzyme in the synthesis of dopamine.

Deficiency of dopamine is the major cause of symptoms in Parkinson's disease, and current treatment involving the administration of L-dopa gives only short-lived respite.

The therapeutic gene may be inserted into any region of the viral genome which is non-essential for culture of the virus, i.e. replication of the virus outside the body, particularly in tissue culture.

The insertion of the therapeutic gene could be made

in the coding sequences or in flanking control regions of the following HSV genes:

1. The thymidine kinase gene. This is the preferred choice since thymidine kinase is important for pathogenicity of HSV, so that deactivation of its gene may reduce potential pathogenicity of the mutant vector.
2. The deoxyuridine triphosphatase (dUTPase) gene
3. The Uracil-DNA glycosidase gene
4. The US1 gene (otherwise named the IE68 gene)
5. The US2 gene
6. The US3 (otherwise, the protein kinase) gene
7. The US4 (otherwise glycoprotein G) gene
8. The US5 gene
9. The US7 (otherwise glycoprotein I) gene
10. The US8 (otherwise glycoprotein E) gene
11. The US9 gene
12. The US10 gene
13. The US11 gene
14. The US12 (otherwise IE12) gene.
15. The UL55 gene
16. The UL56 gene
17. The gene encoding the latency-associated transcripts
18. The IE110 gene

The US nomenclature system is a systematic one. Many of the genes also have common names.

Generally, the promoter should be capable of operation in neuronal cells during the latency stage of

HSV-1, for example promoters which control the latency-associated transcripts (LAT's) of HSV-1, or the promoter which controls the neurofilament gene.

Another aspect of the invention relates to the use of the HSV-1 mutant in the therapy of disease, particularly diseases due to or associated with genetic deficiency.

A further aspect of the invention relates to a pharmaceutical composition for administering the mutant virus comprising the virus in a pharmaceutically acceptable carrier.

Examples

The production of an HSV-1 virus vector in1814 and evaluation of its ability to infect mice neuronal cells (and remain in the latent stage) without in vivo replication and appearance of the disease will now be described by way of example only.

Thereafter there is described, also by way of example only, the insertion of a gene (the gene coding for β -galactosidase) into the viral vector in1814 to produce the viral vector in1850, and expression thereof. The β -galactosidase gene is inserted in order to validate the technology (the presence of the gene being easily detectable). For therapeutic applications, a therapeutic gene would be inserted in an analogous manner, or the β -galactosidase gene in 1850 could be directly replaced by the therapeutic gene.

(I) Production and Evaluation of Viral Vector in1814

Experimental procedures.

Cell culture, virus titration and preparation of virus stocks. Subconfluent monolayers of baby hamster kidney (BHK) 21 clone 13 cells, were infected with HSV-1 strain 17⁺ (Brown et al., 1973), insertion mutant in1814 (Ace et al., 1989) or revertant 1814R (Ace et al., 1989) to produce virus stocks for the infection of mice. The viruses were titrated on BHK cells and virus particle concentrations were determined by electron microscopy with latex bead standards. The viral stocks used in PFU/ml (particles/ml) were: 17⁺ - 5×10^8 (3.1×10^9); 1814R - 5×10^8 (5.1×10^9); in1814 - 1.3×10^7 (1.2×10^{11}).

Comparison of viral titers on cells expressing Vmw65. HSV-1 strain 17⁺, in1814 and 1814R were titrated on MTX5 cells, which are derived from L TK⁻ cells and express Vmw65 (Kmetz et al., 1988). The titers were compared on CV-1, L TK⁻, and MTX5 cells to determine which cell line would be most sensitive for plaque assay of in1814 during acute infection and for explant reactivation from trigeminal ganglia. Although the MTX5 cells provided Vmw65 in trans, and did complement in1814 when compared with L TK⁻ cells, the titers of in1814 were not greater on MTX5 cells than on CV-1 (data not shown). Moreover, in1814 did not form distinct plaques on MTX5, which made the determination of viral titers less exact and more difficult than on CV-1. Thus, CV-1 cells were used as indicator cells in most experiments. In order to increase the sensitivity of this assay, ultraviolet-irradiated tsK virus was absorbed to CV-1 cells at 0.1 PFU per cell (based on titer before UV irradiation) and in1814 from the primary stock as well as trigeminal ganglia homogenates were titrated on these cells. This procedure increases the plaque formation ability of in1814 by 3 log (Ace et al., 1989) so that the particle/PFU ratio similar to that of the wild type virus.

Infection of mice and viral titers during acute infection.

Following corneal scarification, 4 to 6 week old female BALB/cBYJ mice (Jackson Laboratories) or BALB/c (Harlan Sprague Dawley) were infected with approximately 10^5 PFU/eye of 17⁺, 1814R or in1814 (Table 1). Starting at day one post infection, mice were sacrificed by cervical dislocation. corneas were swabbed under sterile conditions with cotton tip

- 11 -

applicators and the applicators were incubated with CV-1 cells. Trigeminal ganglia and eyes were removed aseptically, homogenized in 1ml media without serum, and titered for infectious HSV-1 on CV-1 or on MTX5 cells, as described above.

Explant reactivation.

A. At a minimum of 4 weeks after infection, latently infected mice were sacrificed, the trigeminal ganglia were removed and incubated with monolayers of CV-1 cells. Mice were from a group infected at 10^5 PFU/eye with 17+, 1814R or in1814 or at equal particle number of approximately 10^6 /eye (Table 2). Another infection was done with 10^4 particles/eye of in1814. The monolayers were inspected daily for signs of cytopathic effect. Every 4-6 days ganglia were transferred to new monolayers of cells and observed until reactivation occurred, or for a maximum of 35 days. After reactivation, the virus containing media were removed and saved for DNA extraction. As a latency control, ganglia which were titered at explant, from mice 5 and 7 weeks after infection, were negative for infectious virus.

B. In order to determine the time at which in1814 latency was established, trigeminal ganglia were removed at the indicated times post infection from mice infected with in1814 for explant reactivation and to titer infectious virus in ganglion homogenates. As a control, trigeminal ganglia from mice infected with 17+ were explanted and the monolayer of cells observed daily for cytopathic effect.

Extraction and quantitation of latent viral DNA from trigeminal ganglia. DNA was extracted from trigeminal ganglia, as described previously (Rock and Fraser, 1983). 5 μ g from each sample of 3 pairs of trigeminal ganglia were spotted on a nitrocellulose filter, wetted with 6 x SSC, baked for 2hr at 80°C, and hybridized with a nick translated 32 P-labeled HSV-1 (F) virion DNA probe. After washing, the filter was autoradiographed with XAR-5 (Kodak) film and an intensifying screen at -70°C.

DNA extraction from reactivated virus. Individual plaques of reactivated virus were used to infect CV-1 cells and grow viral stocks.

- 12 -

Nucleoprotein associated HSV-1 DNA was prepared from cytoplasmic fraction of infected cells as described by Pignatti et al. (1979). Briefly, infected cells were lysed by 0.25% Triton X-100, 10 mM EDTA, 10mM tris-HCl, pH 7.9 (final concentration 1.5×10^7 cell/ml) and incubated at room temperature for 10 min with gentle mixing. NaCl was then added to a final concentration of 0.2M and centrifuged at $100 \times g$ at 4°C for 10 min. The supernatant was incubated with 100 $\mu\text{g/ml}$ proteinase K and 0.2% SDS at 37°C for 2 hours and DNA was extracted with phenol, phenol-chloroform and chloroform followed by ethanol precipitation. DNA amounts were measured by A_{260} .

DNA analysis. DNA was cut with restriction enzyme BamHI, resolved by 0.8% agarose gel electrophoresis, Southern blot transferred to nitrocellulose, hybridized with HSV-1 (F) restriction fragment BamHI F and washed by standard procedures (Rock and Fraser, 1983). The filters were autoradiographed with XAR-5 film at -70°C with intensifying screens (Du Pont).

Preparation of ^{32}P -labelled probes. Total HSV-1 DNA was isolated from virions and purified by CsCl gradient centrifugation. The BamHI F restriction fragment of HSV-1 (strain F) cloned into pBR322 was a generous gift of B. Roizman (Post. et al. 1980). Restriction enzymes were purchased from Boehringer Mannheim Biochemicals and used as recommended by the manufacturer. DNA probes were nick-translated by a standard procedure (Maniatis et. al., 1982). The probes were separated from unincorporated nucleotides by passage through Sephadex G-50 mini spin columns (Boehringer). The specific activities of the probes were at least 8×10^7 cpm/ μg of DNA.

Results

Acute viral replication in eyes and trigeminal ganglia of mice and mortality rates.

A. Corneas and eyes. Following corneal inoculation with the parental virus 17⁺, or the revertant 1814R, infectious virus was detected in corneal swabs for 5 days post infection (Table 1), while in1814 was only detected in 8/8 corneal swabs on the first day post-infection and in 3/8 on the second day. Both 17⁺ and 1814R reached titers of about 10⁴ PFU/eye (Figure 1), with the peak titers occurring on the third and second days post-infection, respectively. The titers of in1814 in eye homogenates were approximately 10² PFU on the first day post-infection, and dropped below detection by the third day. To examine the possibility that the infectious in1814 virus present in eye homogenates was due to remnants of the viral inoculum rather than viral replication, the viral stock used to infect mice was incubated at 37°C and titered daily. On each of the three days the titer of in1814 incubated at 37°C was greater than the titer in eye homogenates of in1814 infected mice (data not shown). To increase the detection of in1814, Vmw65 was provided in trans to the indicator cells with an ultraviolet inactivated HSV-1 strain, tsK (Ace et al., 1989), which restores the particle/PFU ratio of in1814 to that of the wild-type virus. While the in1814 titer of the stock used to infect mice was increased 1000 fold by tsK, no infectious in1814 was detected in eye homogenates during days 3-5 post infection.

B. Trigeminal ganglia. The peak of viral replication in the trigeminal ganglia for 17⁺ and 1814R was on the fifth day post-infection, after which viral titers declined until day 11 (Figure 2). No infectious in1814 was detectable in trigeminal ganglia throughout this period, when titered on CV-1 (Figure 2). To increase the sensitivity of the assay, entire trigeminal ganglia homogenates from in1814 infected mice were incubated with CV-1 cells in 6 well plates without added immunoglobulin. Infectious in1814 virus was not detected by this procedure. In another set of experiments Vmw65 was provided in trans to the indicator cells by i) using MTX5 cells (constitutively expressing Vmw65, Kmetz et al, 1988), or ii) by prior

- 14 -

infection with ultraviolet inactivated tsK virus. No infectious in1814 was detected in trigeminal ganglia homogenates during days 3-5 post infection by these methods.

C. Mortality. While mortality rates of mice infected with 17⁺ and 1814R were similar and ranged between 35-60% in independent experiments, none of 127 in1814 infected mice died.

Explant reactivation of latent 17⁺, 1814R and in1814.

A. Mice infected at equal PFU. Reactivation of latent HSV-1 was assayed at 28-37 days post infection by incubating explanted ganglia with monolayers of susceptible cells (CV-1), and inspecting them daily for cytopathic effects. In all mice infected with strain 17⁺ (7 mice, 14/14 ganglia) reactivation was detectable between 5 and 6 days post explant (Table 2). Similarly, in the trigeminal ganglia of mice infected with 1814R reactivation occurred in all animals examined (24/24 ganglia) between days 5 to 9 post-explant. Reactivation of latent in1814 from trigeminal ganglia was detected in all latently infected mice (19/20 trigeminal ganglia) between 5 to 10 days post-explant. No infectious virus was detectable in latently infected ganglia at explant, as measured by virus titer of ganglionic homogenates.

B. Mice infected at equal particle numbers. Since there was a 3 log difference in particle/PFU ratio between 17⁺ (or 1814R) and in1814 (Table 2), the in1814 inoculum of equal PFU contained approximately 10^3 more particles than 17⁺ or 1814R. We therefore examined the ability of in1814 to form a latent infection with equal numbers of inoculated particles. In mice infected with 1.45×10^6 particles (1.6×10^2 PFU), reactivation from latent infection was apparent at 6-8 days post-explant in 4/14 trigeminal ganglia. Thus, in1814 can form latent infection at particle numbers equivalent to those of 17⁺ and 1814R. However, reactivation was not observed from the trigeminal ganglia of 7 mice infected with 1.45×10^4 particles (1.6 PFU) of in1814.

Analysis of reactivated viral DNA. To confirm that the insertion in the Vmw65 gene of in1814 remained unchanged during latent infection,

- 15 -

Southern blots were carried out with BamHI digested DNA isolated from reactivated 17⁺, 1814R and in1814, and hybridized with nick-translated HSV-1 (strain F) BamHI restriction fragment F, which encodes Vmw65.

The data demonstrate that the 12 bp insertion introduced into Vmw65 of in1814 was preserved during latency and reactivation. Since the insertion in in1814 contains a BamHI restriction site (Ace et al., 1989), two BamHI restriction fragments (5 and 3 kb) hybridized with BamHI F in in1814 and in reactivated isolates from in1814 infected trigeminal ganglia. A single 8 kb band was present with 17⁺ and 1814R DNA. The profiles of reactivated 17⁺, 1814R and in1814 were the same as previously described, and identical to the patterns of the viruses used for infection (Ace et al., 1989).

Quantitation of latent viral DNA in mice trigeminal ganglia. Since HSV-1 replication was not detected in trigeminal ganglia during acute infection of in1814, it was important to determine whether this resulted in reduced amounts of in1814 DNA in the ganglia during latent infection. Somewhat unexpectedly, the amounts of latent in1814 DNA were comparable to the amounts present during latent infection of either 17⁺ or 1814R and ranged between dilutions of 10⁻⁴ to 10⁻⁵ (w/w) which correspond to 4 to 0.4 HSV-1 genome equivalents per cell.

When is latency established? Since infectious in1814 was not detected in mouse trigeminal ganglia, but latent infection was established, in1814 provided a unique opportunity to determine when latency begins. Operationally, a latently infected tissue is defined by; i) the absence of infectious virus, and ii) the capacity to reactivate infectious virus (for a review see Hill, 1985). Trigeminal ganglia from mice infected with in1814 were explanted starting at 12hr post infection. Reactivated virus could be detected in 7/14 ganglia at 24hr post infection, in 9/10 at 36hr post infection, in 13/14 at 48hr post infection and in all explanted ganglia from the third day post infection. The elapsed time before detection of reactivated virus was similar for all explant time points, ranging between 5 to 10 days post-explant, and similar to the time required to detect reactivated virus from trigeminal ganglia explanted at one month post infection. No infectious virus was detectable in any in1814 trigeminal

- 16 -

ganglia homogenates during this time period (see figure 2). In contrast, trigeminal ganglia explanted from 17⁺ acutely infected mice contained infectious virus (Figure 2) and caused cytopathic effect within 2 to 3 days post explant which was faster than reactivation of latent virus from ganglia explanted from latent 17⁺ mice at one month post infection (5-6 days, see above).

- 17 -

Table 1. Virus positive corneal swabs
following corneal infection*.

Virus	17+	1814R	<u>in</u> 1814
day 1	8/8	8/8	8/8
day 2	8/8	8/8	3/8
day 3	8/8	7/8	0/8
day 4	7/8	6/8	0/8
day 5	4/8	4/8	0/8
day 7	0/8	0/8	0/8

* number of virus-positive corneas/total corneas

- 18 -

Table 2. Reactivation of latent in1814, 1814R and 17⁺ from mice infected with equal PFU or equal particles.

Virus	17 ⁺	1814R	<u>in</u> 1814	<u>in</u> 1814	<u>in</u> 1814
Inoculum/mouse					
PFU	1.3 X 10 ⁵	1.3 X 10 ⁵	1.3 X 10 ⁵	1.6 X 10 ²	1.6 X 10 ⁰
Particles	7.8 X 10 ⁵	1.5 X 10 ⁶	1.2 X 10 ⁹	1.5 X 10 ⁶	1.5 X 10 ⁴
Reactivation*	14/14	24/24	19/20	4/14	0/14

* Reactivation positive trigeminal ganglia/total number of trigeminal ganglia explanted for co-cultivation.

(II) Production and Expression of inl850 (containing β -gal gene)

Experimental Procedures

1. Construction of plasmid pTKLATEX

Plasmid pGx166 was obtained from Dr V G Preston. It consists of the previously described plasmid pTK1 (Wilkie et al, 1979) with an XhoI linker inserted into the unique SstI site in the thymidine kinase (TK) coding sequences. The HindIII site in the vector (pAT153) sequences of pGx166 was removed by cleaving with HindIII, end-filling with T4 DNA polymerase and self ligation, to yield pGX166 Δ H3. Plasmid pFJ3 was obtained from Dr F J Rixon. It was derived from pCH110 (Pharmacia) by insertion of an XbaI linker into the PvuII site at the upstream extremity of the SV40 enhancer/promoter region. The β -galactosidase gene, under the control of the SV40 enhancer/promoter, was excised from pFJ3 as a 4073bp XbaI/BamHI fragment and cloned between the XbaI and BamHI sites of pUC18(Xho). Plasmid pUC18(Xho) was constructed by insertion of an XhoI linker into the SmaI site of pUC18. The resulting plasmid was named pUC18 β gal.

Plasmid pTKEX was constructed from pGX166 Δ H3 and pUC18 β gal by cloning the XhoI/SalI fragment of pUC18 β gal, containing the β -galactosidase gene, into the XhoI site of pGX166 Δ H3 (Figure 4). A 605bp PvuI fragment that is known to contain the LAT promoter (Batchelor and O'Hare, 1990) was cloned into the HincII site of pUC18, after first treating with T4 DNA polymerase to create blunt ends, to give pUCLAT. The orientation of the inserted fragment was such that transcription of LAT proceeded away from the HindIII site of pUC18. Plasmid pTKEX was cleaved with XbaI and HindIII and the large fragment isolated, and pUCLAT was cleaved with XbaI and HindIII and the small fragment isolated. These two DNA

fragments were ligated together to yield pTKLATEX (Figure 4).

Construction of the herpes simplex virus mutant inl850

Plasmid pTKLATEX was cotransfected into BHK cells together with inl814 DNA, using standard techniques (Preston, 1981). Progeny viruses were subjected to multiple rounds of plaque purification with Southern hybridisation used to screen for viruses containing the pTKLATEX insert at each stage, using methods described previously (Ace et al, 1989). Cell and viral DNA from the amplified progeny of isolated plaques was cleaved with EcoRI, transferred to nylon 'Genescreen plus' membrane, and probed with radiolabelled 2500bp EcoRI fragment of pGX166 Δ H3 (Figure 4). Viral DNA without insert yielded the 2500bp band, whereas virus containing the insert yielded two bands, of approximately 5650bp and 1250bp (Figure 4). A virus preparation that contained the pTKLATEX insert but no detectable contamination with inl814 was named inl850.

Expression of β -galactosidase

BHK monolayers were infected with 100 particles of inl850 per cell and incubated at 37 $^{\circ}$. At 3h and 6h post infection, cells were harvested, cytoplasmic extracts made and β -galactosidase activity measured, as described previously (McKee et al, 1990).

RESULTS

Plasmid pTKEX

To facilitate transfer of genes into the HSV-1 genome, plasmid pTKEX was constructed. The plasmid contains a composite gene, consisting of the prokaryotic β -galactosidase gene controlled by the SV40 enhancer/promoter region, inserted into and disrupting the coding sequences of the HSV-1 thymidine kinase (TK) gene. Plasmid pTKEX is particularly useful for the cloning of promoter sequences or coding sequences, due to the possession of unique restriction endonuclease cleavage sites. Thus, promoter sequences can be introduced between the unique XbaI and HindIII sites, and coding regions can be cloned between the unique HindIII and XhoI sites. Once manipulations of this type have been performed, the resultant plasmids can readily be recombined with HSV-1 DNA or genomic DNA derived from HSV-1 mutants. Recombinants can be identified by the ability to form blue plaques after X-gal overlay, if the β -galactosidase gene is retained. Selection for recombinants may also be achieved by propagation in the presence of compounds, such as 5-bromodeoxyuridine or acyclovir, that are metabolised to inhibitory products by HSV-1 TK. A further means of identifying recombinant viruses containing inserts derived from pTKEX is by restriction of DNA and subsequence 'Southern' blot hybridisation.

Plasmid pTKLATEX

Using the methods described above, the LAT promoter described by Batchelor and O'Hare (1990) was cloned between the XbaI and HindIII sites of pTKEX, replacing the SV40 enhancer/promoter. In

pTKLATEX, the LAT promoter controls the expression of β -galactosidase.

HSV-1 mutant inl850

Plasmid pTKLATEX was recombined with inl814 DNA, and a virus preparation possessing the inserted DNA was isolated and named inl850. When inl850 DNA was cleaved with EcoRI and probed with a radiolabelled 2500bp EcoRI fragment derived from pGX166 Δ H3, hybridisation was noted to fragments of 5650bp and 1250bp, but not to the 2500bp EcoRI fragment present in inl814 DNA. Thus inl850 is pure, containing no detectable contamination with residual inl814.

Expression of β -galactosidase by inl850

When BHK monolayers were infected with inl850, an increase in β -galactosidase activity was observed (Table 3), demonstrating that the LAT promoter is active in inl850. Thus the coding sequences for any gene of interest, for example a therapeutic gene, may be introduced into the inl814 genome under the control of the LAT promoter. This would be achieved by cloning the coding sequences of the therapeutic gene between the HindIII and XhoI sites of pTKLATEX, then recombining the new plasmid DNA with inl850 DNA. Preliminary selection of recombinants would be achieved by screening for the inability to form blue plaques in the presence of X-gal, an final verification of recombinant structures would be achieved by Southern blot hybridisation.

Table 3

Cell Extract

 β -galactosidase activity
(arbitrary units per 2×10^5 cells)

Mock infected

0.350

inl850 infected,
3h post infection

1.135

inl850 infected,
6h post infection

2.790

- 24 -

Figures.

Figure 1. HSV-1 titers in mouse eyes during acute infection. Each point represents the geometric mean titer from 8 individually titrated eyes at the indicated time (days) post infection, from two experiments. The titers are plotted on a logarithmic scale as plaque forming units/eye (PFU/eye). Closed squares - in1814, open diamonds - 17+, closed diamonds - 1814R.

Figure 2. HSV-1 titers in mouse trigeminal ganglia during acute infection. Each point represents the geometric mean titer from 8 ganglia titrated individually at the indicated time (days) post infection, from two experiments. The titers are plotted on a logarithmic scale as plaque forming units/trigeminal ganglia (PFU/TG). Open diamonds - Strain 17+. Closed diamonds - revertant 1814R. No infectious in1814 was detected during acute infection (Closed squares).

Figure 3. Time of establishment of HSV-1 latent in1814 infection in the trigeminal ganglia of mice. A ganglion was scored positive for reactivation when cytopathic effects were detected in the CV-1 monolayer. The numbers are cumulative data from three different experiments: Data is given in percentage of reactivated ganglia at each time point, 10-14 ganglia/point.

Figure 4Derivation of pTKLATEX

Abbreviations of restriction endonuclease cleavage sites are:
B, BamHI; H, HindIII; R, EcoRI; S, SalI; Xb, XbaI; Xh, XhoI. The
2500 bp EcoRI from pGX166ΔH3, used as a probe for Southern
hybridisation, and the 5650 and 1250 bp fragments from pTKLATEX,
are shown.

Post, L.E., Mackem, S. and Roizman, B. (1981). Regulation of α genes of herpes simplex virus: expression of chimeric genes produced by fusion of thymidine kinase with α gene promoters. Cell 24, 555-565.

Preston, C.M. (1979). Control of herpes simplex virus type 1 mRNA synthesis in cells infected with wild-type virus or the temperature-sensitive mutant tsK. J. Virol. 29, 275-284.

Preston, C.M., Cordingley, M.G. and Stow, N.D. (1984). Analysis of DNA sequences which regulate the transcription of a herpes simplex virus immediate early gene. J. Virol. 50, 708-716.

Preston, C.M., Frame, M.C. and Campbell, M.E.M. (1988). A complex formed between cell components and a herpes simplex virus structural polypeptide binds to a viral immediate early gene regulatory DNA sequence. Cell 52, 425-434.

Preston, V.G. (1981). Fine-structure mapping of herpes simplex virus type 1 temperature-sensitive mutations within the short repeat region of the genome. Journal of Virology 39, 150-161.

Rock, D.L. and Fraser, N.W. (1983). Detection of HSV-1 genome in the central nervous system of latently infected mice. Nature (London) 302, 523-525.

Roizman, B. and Sears, A.E. (1987). An inquiry into the mechanisms of herpes simplex virus latency. Ann. Rev. Microbiol. 41, 543-571.

Sacks, W.R., Greene, C.D., Aschman, D.P. and Schaffer, P.A. (1985). Herpes simplex virus type 1 ICP27 is an essential regulatory protein. J. Virol. 55, 796-805.

Spivack, J.G. and Fraser, N.W. (1987). Detection of herpes simplex type 1 transcripts during latent infection in mice. J. Virol. 61, 3841-3847.

Spivack, J.G. and Fraser, N.W. (1988a). Expression of herpes simplex virus type 1 latency-associated transcripts in the trigeminal ganglia of mice during acute infection and reactivation of latent infection. J. Virol. 62, 1479-1485.

Spivack, J.G. and Fraser, N.W. (1988b). Expression of herpes simplex type 1 (HSV-1) latency-associated transcripts and transcripts affected by the deletion in avirulent mutant HFEM: Evidence for a new class of HSV-1 genes. J. Virol. 62, 3281-3287.

Steiner, I., Spivack, J.G., Lirrete, R.P., Brown, S.M., MacLean, A.R., Subak-Sharpe, J. and Fraser, N.W. (1989). Herpes simplex virus type 1 latency-associated transcripts are evidently not essential for latent infection. The EMBO J. 8, 505-511.

Steiner, I., Spivack, J.G., O'Boyle, D.R., Lavi, E. and Fraser, N.W. (1988). Latent herpes simplex virus type 1 transcription in human trigeminal ganglia. J. Virol. 62, 3493-3496.

Stevens, J.G., Wagner, E.K., Devi-Rao, G.B., Cook, M.L. and Feldman, L.T. (1987). RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. *Science* 235, 1056-1059.

Stroop, W.G., Rock, D.L. and Fraser, N.W. (1984). Localization of herpes simplex virus in the trigeminal and olfactory systems of the mouse central nervous system during acute and latent infections by in situ hybridization. *Lab. Invest.* 51, 27-38.

Wilkie, N.M., Clements, J.B., Boll, W., Mantei, W., Lonsdale, D. and Weissmann, C. (1979). Hybrid plasmids containing an active thymidine kinase gene of herpes simplex virus 1. *Nucleic Acids Research* 7, 859-877.

The Claims

1. A herpes simplex virus type 1 (HSV-1) mutant capable of establishing latent infection in the absence of in vivo viral replication in neuronal cells and of expressing an inserted therapeutic gene, which comprising

(i) a DNA sequence change in the gene coding for Vmw65 protein, such as to substantially remove the transinducing properties whilst retaining its structural role and thereby preventing in vivo replication, the DNA sequence change being achieved by a transition or transversion alteration of 1 to 72 base pairs, an oligonucleotide insert of 3 to 72 base pairs, or a deletion of 3 to 72 base pairs, at a position between amino acids 289 and 412 of the protein; and

(ii) a therapeutic gene inserted into a region of the HSV-1 genome which is non-essential for culture of the virus, and a promoter therefor able to express the therapeutic gene in neuronal cells in vivo.

2. A virus according to claim 1, wherein the DNA sequence change is achieved by insertion of an oligonucleotide sequence.

3. A virus according to claim 2, wherein the therapeutic gene is inserted into in1814 viral vector.

4. A virus according to claim 1, wherein the therapeutic gene is a tyrosine hydroxylase gene.

5. A virus according to claim 1, wherein the therapeutic gene is selected from nerve growth factor beta subunit gene, hypoxanthine-guanine phosphoribosyl transferase gene, beta-hexosaminidase alpha chain gene, and HIV ref gene.
6. A virus according to claim 1, wherein the therapeutic gene is inserted in the coding sequence or in the flanking control region of the thymidine kinase gene.
7. A virus according to claim 1, wherein the therapeutic gene is inserted in the coding sequence or in a flanking control region of an HSV gene selected from:
deoxyuridine triphosphatase gene, uracil-DNA glycosidase gene, US1 gene, US2 gene, US3 gene, US4 gene, US5 gene, US7 gene, US8 gene, US9 gene, US10 gene, US11 gene, US12 gene, UL55 gene, UL56 gene, the gene encoding the latency-associated transcripts, and the IE 110 gene.
8. A virus according to claim 1, wherein the promoter for the therapeutic gene is a promoter controlling production of the latency-associated transcripts.
9. A virus according to claim 1, wherein the promoter for the therapeutic gene is a promoter which controls the HSV neurofilament gene.
10. A virus according to claim 1 which is in1850.
11. A composition for administration of the mutant virus, which comprises the virus of claim 1 in a pharmaceutically

acceptable carrier.

12. Plasmid pTKLATEX, or plasmid pTKEX.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. PCT/GB 90/01276**

SA

35250
19060

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 01/11/90
The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A2- 0282330	14/09/88	EP-A-	0349598	10/01/90
		WO-A-	88/07083	22/09/88
EP-A2- 0243155	28/10/87	AU-B-	585126	08/06/89
		AU-D-	6861487	29/10/87
		JP-A-	62257385	09/11/87
		US-A-	4859587	22/08/89
EP-A1- 0176170	02/04/86	JP-A-	61001390	07/01/86
		US-A-	4859587	22/08/89

For more details about this annex : see Official Journal of the European patent Office, No. 12/82


This Page Blank (uspto)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Science, Vol. 241, September 1988, Alfred I Geller et al.: "A Defective HSV-1 Vector Expresses Escherichia coli B-Galactosidase in Cultured Peripheral Neurons ", see page 1667 - page 1669 see the whole document --	1-3,6,7, 11
Y	EP, A2, 0243155 (INSTITUT MERIEUX) 28 October 1987, see pages 13-18 and fig. 1 --	1-3,6,7, 11
A	EP, A1, 0176170 (INSTITUT MERIEUX) 2 April 1986, see pages 5-11 -- -----	1


INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 90/01276


I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 12 N 7/01, 15/86, 15/38		
II. FIELDS SEARCHED Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC5	C 12 N	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	JOURNAL OF VIROLOGY, Vol. 63, No. 5, May 1989, Chris I. Ace et al.: "Construction and Characterization of a Herpes Simplex Virus Type 1 Mutant Unable To Transinduce Immediate-Early Gene Expression ", see page 2260 - page 2269 see the whole document	1-3,6,7, 11
A	EP, A2, 0282330 (SCHERING CORPORATION) 14 September 1988, see page 2, line 56 - page 5	1-15
A	Science, Vol. 244, June 1989, Theodore Friedmann: "Progress Toward Human Gene Therapy ", see page 1275 - page 1280 see page 1277	1
<p>* Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
19th November 1990	14. 12. 90	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	Natalie Weinberg	

FIG. 3

This Page Blank (uspto)

FIG. 2

This Page Blank (uspto)



Days post infection

FIG. 1

This Page Blank (uspto)